Anika Therapeutics spent most of the past decade as a small, single-customer hyaluronic-acid specialist whose fortunes were yoked to J&J MedTech and a slow-moving regulatory pipeline. Q2 FY2026 is the quarter that changed the lens. Revenue of $32.6 million rose 16% year over year, gross margin expanded 14 points to 65%, GAAP net income from continuing operations of $3.3 million (a swing of $8.0 million from a $4.6 million loss a year ago) and adjusted EBITDA of $7.1 million - the highest the company has printed since 2020. The Commercial Channel, the smaller of the company's two engines, set an all-time revenue record at $13.9 million and grew 17%, while the OEM Channel (which is, by management's own admission, essentially a J&J relationship) grew 14% on stronger transfer unit volumes. Management used the result to lift full-year 2026 guidance: total revenue growth is now 5–10% (up from 1–9%), OEM growth is 0–5% (from down 5% to flat), Commercial growth is 12–18% (from 10–20%), and adjusted EBITDA margin is 13–17% (up from 5–10%). The print also pulled forward one consequential change: starting with the 2027 outlook, Anika will only forecast revenue from products that have received regulatory approval, which strips Hyalofast - the cartilage-repair PMA still under FDA review - out of forward guidance until approval lands.
There are two ways to read the quarter, and both are partly right. The first is the clean story: cost actions taken earlier in the year, a richer sales mix toward higher-margin J&J Monovisc volumes, and a record Commercial quarter combined to expand operating leverage faster than the topline moved. The second is the careful story: more than half of every revenue dollar still comes from a single customer, the OEM growth came with a $2.9 million price concession in the quarter, the FDA has the Hyalofast PMA and the Cingal NDA both on its desk, and the company has burned through 75% of its buyback authorization with $10.0 million still authorized at quarter-end. The stock reacted well - up 6.7% to $16.17 on the day, then continued to $22.03 by August 12, a 52-week high. Net of a J&J MedTech OEM mix, the quarter is a real operational turn; with it, the quarter is a real re-rating candidate whose valuation is being paid forward on a regulatory outcome that has not happened yet.